Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Haas

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Anti-Cancer Drugs|June 6, 2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancerArndt Stahler, Volker Heinemann, Jens Neumann, et al.
Nature Cancer|September 3, 2021
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune responseLaura Poillet-Perez, Daniel W Sharp, Yang Yang, et al.
Nature Cancer|February 5, 2022
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune responseLaura Poillet-Perez, Daniel W Sharp, Yang Yang, et al.
Scientific Reports|December 8, 2025
Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunich<sup>LMU</sup> outpatient clinicKlara Dorman, Kilian Breitenwieser, Laura Fischer, et al.
ACS Nano|February 18, 2017
On-Surface Site-Selective Cyclization of Corrole RadicalsStefano Tebi, Mateusz Paszkiewicz, Hazem Aldahhak, et al.
BMC Cancer|August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2023
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Volker Heinemann, Laura E Fischer, et al.
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
Targeted Oncology|February 28, 2023
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKlara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Anti-Cancer Drugs|June 6, 2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancerArndt Stahler, Volker Heinemann, Jens Neumann, et al.
Nature Cancer|September 3, 2021
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune responseLaura Poillet-Perez, Daniel W Sharp, Yang Yang, et al.
Nature Cancer|February 5, 2022
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune responseLaura Poillet-Perez, Daniel W Sharp, Yang Yang, et al.
Scientific Reports|December 8, 2025
Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunich<sup>LMU</sup> outpatient clinicKlara Dorman, Kilian Breitenwieser, Laura Fischer, et al.
ACS Nano|February 18, 2017
On-Surface Site-Selective Cyclization of Corrole RadicalsStefano Tebi, Mateusz Paszkiewicz, Hazem Aldahhak, et al.
BMC Cancer|August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2023
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Volker Heinemann, Laura E Fischer, et al.
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
Targeted Oncology|February 28, 2023
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKlara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Pageof 18